References
1. Selcuck A, Kilic Y, Korun O, et al. High incidence of fever in
patients after biointegral pulmonic valved conduit implantation. J
Card Surg. DETAILS TO BE CONFIRMED
2. Abolhoda A, Yu S, Oyarzun JR, McCormick JR, Bogden JD, Gabbay S.
Calcification of bovine pericardium: Glutaraldehyde versus No-React
biomodification. Ann Thorac Surg . 1996;62(1):169-174.
doi:10.1016/0003-4975(96)00277-9
3. Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late
Causes of Death After Pediatric Cardiac Surgery. J Am Coll
Cardiol . 2016;68(5):487-498. doi:10.1016/j.jacc.2016.05.038
4. Marianeschi SM, Iacona GM, Seddio F, et al. Shelhigh No-React porcine
pulmonic valve conduit: A new alternative to the homograft. Ann
Thorac Surg . 2001;71(2):619-623. doi:10.1016/S0003-4975(00)02456-5
5. Grohmann J, Höhn R, Fleck T, et al. No-React® Injectable
BioPulmonicTM valves re-evaluated: Discouraging
follow-up results. Interact Cardiovasc Thorac Surg .
2015;21(5):657-665. doi:10.1093/icvts/ivv214
6. Ishizaka T, Ohye RG, Goldberg CS, et al. Premature failure of
small-sized Shelhigh No-React porcine pulmonic valve conduit model
NR-4000. Eur J Cardio-thoracic Surg . 2003;23(5):715-718.
doi:10.1016/S1010-7940(03)00080-0
7. Sahin A, Müggler O, Sromicki J, et al. Long-term follow-up after
aortic root replacement with the Shelhigh® biological valved conduit: A
word of caution! Eur J Cardio-thoracic Surg .
2016;50(6):1172-1178. doi:10.1093/ejcts/ezw167
8. Reineke DC, Kaya A, Heinisch PP, et al. Long-term follow-up after
implantation of the Shelhigh® No-React® complete biological aortic
valved conduit. Eur J Cardio-thoracic Surg . 2016;50(1):98-104.
doi:10.1093/ejcts/ezv452
9. Kaya A, Heijmen RH, Kelder JC, Schepens MA, Morshuis WJ. Stentless
biological valved conduit for aortic root replacement: Initial
experience with the Shelhigh BioConduit model NR-2000C. J Thorac
Cardiovasc Surg . 2011;141(5):1157-1162. doi:10.1016/j.jtcvs.2010.07.009
10. Tweddell JS, Pelech AN, Frommelt PC, et al. Factors affecting longer
of homograft valves used in right ventricular outflow tract
reconstruction for congenital heart disease. Circulation .
2000;102(19). doi:10.1161/01.cir.102.suppl_3.iii-130
11. Niwaya K, Knott-Craig CJ, Lane MM, et al. Cryopreserved homograft
valves in the pulmonary position: Risk analysis for intermediate-term
failure. J Thorac Cardiovasc Surg . 1999;117(1):141-147.
doi:10.1016/S0022-5223(99)70479-4
12. Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova T
V., Kutikhin AG. Degeneration of Bioprosthetic Heart Valves: Update
2020. J Am Heart Assoc . 2020;9(19):e018506.
doi:10.1161/JAHA.120.018506
13. Mery CM, Guzmán-Pruneda FA, De León LE, et al. Risk factors for
development of endocarditis and reintervention in patients undergoing
right ventricle to pulmonary artery valved conduit placement Read at the
95th Annual Meeting of the American Association for Thoracic Surgery,
Seattle, Washington, April 25-29, 2015. In: Journal of Thoracic
and Cardiovascular Surgery . Vol 151. Mosby Inc.; 2016:432-441.e2.
doi:10.1016/j.jtcvs.2015.10.069
14. Beckerman Z, De León LE, Zea-Vera R, Mery CM, Fraser CD. High
incidence of late infective endocarditis in bovine jugular vein valved
conduits. J Thorac Cardiovasc Surg . 2018;156(2):728-734.e2.
doi:10.1016/j.jtcvs.2018.03.156
15. Gröning M, Tahri NB, Søndergaard L, Helvind M, Ersbøll MK, Ørbæk
Andersen H. Infective endocarditis in right ventricular outflow tract
conduits: A register-based comparison of homografts, Contegra grafts and
Melody transcatheter valves. Eur J Cardio-thoracic Surg .
2019;56(1):87-93. doi:10.1093/ejcts/ezy478
Acknowledgement: This study was supported by the British
Heart Foundation and the NIHR Biomedical Research Centre at University
Hospitals Bristol and Weston NHS Foundation Trust and the University of
Bristol.